News and Media – CrannMed

SakuraBead pre-clinical data presented at GEST MSK 2023

We were delighted to have our pre-clinical data on SakuraBead, our resorbable embolization microspheres, presented for the first time at the inaugural GEST MSK 2023…

Dr Yilun Koethe joins CrannMed Advisory Board

The CrannMed team are delighted to welcome Dr Yilun Koethe to their Advisory Board. Dr Koethe will join existing Board members Dr Ari Isaacson, Dr…

New Cleanroom Installation

Last month, we finished the installation and validation of our new, class 8 cleanroom. This was the final step in allowing us to build finished,…

CrannMed moves into new offices – expanding footprint and positioning for growth

CrannMed has expanded into new premises. The company, which formed in 2018, is moving to 6,000 sq ft premises in the Galway Technology Park, Parkmore,…

CrannMed receives €3.5M from Horizon EIC Accelerator

CrannMed has been awarded €3.5m via the highly competitive EU funded Horizon EIC Accelerator project instrument. This 2-year project will fund a pivotal clinical trial,…

SakuraBead consortium wins ‘Disruptive Technologies Innovation Fund’ grant

CrannMed along with their consortium partners are proud to announce that they have been awarded €2.5 Million from the Disruptive Technologies Innovation Funding (DTIF) run…

CrannMed obtains “Breakthrough Device Designation” from the FDA for its innovative Knee Osteoarthritis therapy

CrannMed has obtained a Breakthrough Device Designation by the U.S Food and Drug Administration for its EmboSure Microspheres used to treat patients suffering from…